Success story: one HbA1c FS in India

In the current scenario, the Indian market is witnessing technological innovations in the healthcare sector, which is mostly seen in the point-of-care segment but as well in traditional diagnostics. Many companies are entering the market with bigger modular, track and all-in-one systems so as to improve the turn-around-time (TAT) for better and faster patient care.

DiaSys, a well-established player in the clinical chemistry segment has been innovating its diabetes monitoring portfolio. DiaSys has already launched HbA1c net FS, the gold standard in diabetes testing which offers onboard hemolysing on respons®910. The same has been implemented with one HbA1c FS on SYS 400, evaluated in MV Hospital for Diabetes, Chennai. This hospital is recognized as an internationally known tertiary care centre for referral of diabetic patients requiring super-specialist’s opinion and management. In addition it is a WHO Collaborating Centre for Research, Education & Training in Diabetes.

Onboard hemolysis using one HbA1c FS has thus been successfully evaluated on SYS 400. This made us one of the first companies to implement on board hemolysis successfully in 400 tests throughput instrument class. The evaluation met our criteria, e.g. the CV was found to be <3%. Special thanks to Mr. Rajkumar Jeggaraj, Regional Service Manager (South Zone). Feedback from the customers is very positive and they are happy to have decided for a “SYS 400 system”.

More on https://www.mvdiabetes.com/